HPV genotype as a predictor of bevacizumab treatment response in recurrent respiratory papillomatosis patients

Recurrent Respiratory Papillomatosis (RRP), a challenging condition caused primarily by HPV-6 and HPV-11, is characterized by benign but relentless growths in the airway. While the anti-angiogenic agent bevacizumab has revolutionized adjuvant treatment, response variability among patients remains high, complicating clinical management and highlighting the need for predictive biomarkers to guide personalized therapy.

This research, published in ENT Discovery, presents a robust retrospective analysis correlating HPV genotype with clinical outcomes in RRP patients receiving intralesional bevacizumab. This study demonstrates that patients with HPV-11-positive disease achieved significantly greater reductions in disease burden, longer intervals between surgical interventions, and more frequent complete clinical responses compared to patients with HPV-6-positive disease. These findings suggest that the intrinsic biological behavior of the virus, potentially linked to differential angiogenic factor expression, critically influences the tumor microenvironment's susceptibility to VEGF inhibition.

The establishment of HPV genotyping as a predictive tool represents a major step toward precision medicine in RRP. It enables clinicians to stratify patients at diagnosis, potentially reserving bevacizumab for those with HPV-11-associated disease who are most likely to benefit, while exploring alternative strategies earlier for HPV-6-positive cases. However, the underlying molecular mechanisms driving this differential response require further investigation through translational studies. Additionally, validating these findings in larger, prospective cohorts and across diverse populations is essential before widespread clinical adoption.